Tropic Biosciences UK Ltd.

Based in UK, Tropic Biosciences UK Ltd. is dedicated to enhancing tropical agriculture through innovative genetic solutions, focusing on staple crops like bananas, rice, and coffee. Their technology aims to boost crop resilience and sustainability in agriculture. Based in Norwich, UK, founded in 2016, Gilad M.

Gershon is the Co-founder and CEO, Tropic Biosciences UK Ltd. specializing in advanced genetic solutions for tropical agriculture. In March 2026, Tropic Biosciences UK Ltd. raised USD 105 million in series C funding co-led by Forbion, and Corteva Catalyst, with participation from Aliment Capital, ABN AMRO Ventures, Invest International, Just Climate, IQ Capital, Polaris Partners, Genoa Ventures, Sucden Ventures, Five Seasons Ventures and Temasek Holdings.

Tropic specializes in advancing tropical agriculture through innovative genetic solutions, primarily focusing on staple crops such as bananas, rice, and coffee. Their core offerings include advanced genetic editing technologies, specifically the proprietary GEiGS® platform, which integrates CRISPR gene editing with RNA interference (RNAi). This technology enhances crop resilience to diseases, minimizes reliance on pesticides, and improves overall yield and quality, addressing critical agricultural challenges posed by climate change and population growth. Tropic's products are targeted at a diverse client base, including farmers and agricultural stakeholders in tropical regions across Asia, Africa, and Latin America, aiming to create more productive and sustainable farming practices.

The company works closely with growers to tailor its innovations to local needs, ensuring that their technologies serve as effective tools for enhancing food security globally. Tropic Biosciences generates revenue by licensing its proprietary gene‑editing technologies and crop traits to agricultural producers, seed companies, and commercial partners. The company monetizes improved crop varieties (e. g.

, coffee, banana, rice) through commercial licensing deals, long‑term royalty agreements, and strategic partnerships, enabling higher yields, disease resistance, and supply‑chain efficiencies for growers. The company plans to use the March 2026 funding to expand large-scale plant production, strengthen supply chains, support commercial partnerships, and advance disease‑resistant banana and rice development.